Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do partial agonist beta-blockers have improved clinical utility?

J D Fitzgerald

    Cardiovascular Drugs and Therapy
    |June 1, 1993
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Exercise Interventions for Preserving Physical Function Among Cancer Survivors in Middle to Late Life.

    The Journal of frailty & aging·2016
    Same author

    Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.

    Cold Spring Harbor perspectives in medicine·2014
    Same author

    Assessment and clinical implications of cardioselectivity.

    Proceedings of the Royal Society of Medicine·2010
    Same author

    Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis.

    Lupus·2008
    Same author

    SMI meeting: innovations in cardiovascular drugs. March 3-4, 1999, London, UK.

    Expert opinion on investigational drugs·2005
    Same author

    Distortion of the spermathecae of phytoseiid mites (Acari: Phytoseiidae) in slide preparation.

    Experimental & applied acarology·2001
    Same journal

    GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.

    Cardiovascular drugs and therapy·2026
    Same journal

    Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

    Cardiovascular drugs and therapy·2026
    Same journal

    Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

    Cardiovascular drugs and therapy·2026
    Same journal

    Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

    Cardiovascular drugs and therapy·2026
    Same journal

    Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

    Cardiovascular drugs and therapy·2026
    Same journal

    Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

    Cardiovascular drugs and therapy·2026
    See all related articles

    Beta-blockers with partial agonist properties offer limited proven benefits over full antagonists. Current evidence suggests no significant clinical advantage for these agents in patient care.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Beta-blockers have been used for 30 years, yet optimal pharmacodynamic profiles remain debated.
    • Partial agonism in beta-blockers, exemplified by epanolol, is a focus of ongoing research.

    Discussion:

    • This commentary examines the development and clinical relevance of beta-blockers with partial agonist activity.
    • The study reviews evidence on the impact of partial agonism on beta-blocker efficacy and tolerability.

    Key Insights:

    • Controlled clinical studies provide little convincing evidence that partial agonism offers significant benefits over full antagonists.
    • The clinical utility of partial agonist beta-blockers requires further investigation and robust data.

    Outlook:

    • Future research should focus on identifying specific patient populations or conditions where partial agonist beta-blockers may provide unique advantages.

    Related Experiment Videos

  • Further comparative studies are needed to definitively establish the role of partial agonism in cardiovascular medicine.